Side-by-side · Research reference

TeriparatidevsTesofensine

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AFDA-ApprovedHUMAN-REVIEWED10/62 cited

BPhase 3AUTO-DRAFTED10/40 cited

Teriparatide

PTH (1-34) Fragment · FDA-Approved

20 mcgDaily dose

12-18 moAnabolic windowFerrari 2026

SQRoute

SQ · Thigh/Abdomen · Once Daily

Tesofensine

SNDRI · Phase 3 obesity candidate

0.25–0.5 mgDaily doseAstrup 2008

9.2 kgWeight ↓ (24 wk)Astrup 2008

Phase 3Evidence levelAstrup 2008

Oral · Once daily morning

01Mechanism of Action

Parameter

Teriparatide

Tesofensine

Primary target

Parathyroid hormone 1 receptor (PTH1R) on osteoblastsXue 2026

Serotonin / norepinephrine / dopamine transporters (SERT / NET / DAT)Astrup 2008

Pathway

PTH1R activation → cAMP/PKA signaling → osteoblast differentiation and activity

Triple monoamine reuptake inhibition → ↑synaptic 5-HT, NE, DA → appetite suppression + thermogenesisAstrup 2008

Downstream effect

Stimulates osteoblast formation and bone matrix deposition; increases bone mineral density at trabecular and cortical sites

Strong appetite suppression, mild thermogenic effect, weight lossAstrup 2008

Feedback intact?

Yes — intermittent dosing preserves anabolic effect; continuous exposure causes catabolic bone resorption

—

Origin

Recombinant 34-amino-acid N-terminal fragment of 84-amino-acid human PTH

Small molecule developed by NeuroSearch (Denmark) for CNS indications, repurposed for obesityAstrup 2008

Antibody development

—

02Dosage Protocols

Parameter

Teriparatide

Tesofensine

Standard dose (osteoporosis)

20 mcg / day

FDA-approved regimen for severe osteoporosis.

—

Frequency

Once daily

Intermittent administration preserves anabolic effect.

Once daily, morning

Maximum duration

24 months lifetime

Anabolic effect wanes after 12-18 months; FDA recommends max 2-year cumulative exposure.

—

Hypoparathyroidism dose

20 mcg / day

Used off-label for chronic hypoparathyroidism.

—

Evidence basis

RCT / FDA-approved

Phase 2b + ongoing Phase 3Astrup 2008

Pelvic fragility fractures

20 mcg / day × 8-12 weeks

Accelerates fracture healing; reduces time to union.Crooks 2026

—

Route

Subcutaneous (thigh or abdomen)

—

Timing

Morning or evening (flexible)

Morning to avoid sleep disruption

Storage

Refrigerate 2-8 °C; pen device stable at room temp for 28 days after first use

—

Pharmacogenetics

ALDH2 polymorphisms may influence BMD responseObara 2026

ALDH2*2 variant carriers show altered PTH receptor expression.Obara 2026

—

Standard dose

—

0.25–0.5 mg / dayAstrup 2008

Lower / starter dose

—

0.125 mg / day

Duration

—

24 weeks per studied cycle

Form

—

Oral capsule

Half-life

—

~9 days (very long)

03Metabolic / Fat Loss Evidence

Parameter

Teriparatide

Tesofensine

Fat loss application

None — teriparatide is a bone anabolic agent without direct lipolytic activity

—

04Side Effects & Safety

Parameter

Teriparatide

Tesofensine

Hypercalcemia

Transient serum calcium elevation 4-6 hours post-injection

Monitor serum calcium; usually asymptomatic.

—

Orthostatic hypotension

Dizziness, lightheadedness within hours of injection

—

Nausea

Common, usually mild and transient

Common

Leg cramps / Arthralgia

Musculoskeletal pain reported in clinical trials

—

Hypercalciuria

Increased urinary calcium excretion; monitor for nephrolithiasis risk

—

Osteosarcoma (black box warning)

Rat studies showed dose-dependent osteosarcoma; not observed in humans to date; contraindicated in Paget's disease, skeletal malignancy, prior radiation

—

Injection site reaction

Erythema, bruising, pain (uncommon)

—

Heart rate / BP

—

Dose-dependent ↑ HR + BPAstrup 2008

Insomnia

—

Dose-related; mitigate with morning timing

Dry mouth

—

Common

Mood changes

—

Anxiety / agitation possible

Cardiovascular events

—

Phase 3 trial monitoring; not yet FDA-cleared

Pregnancy / OB

—

Contraindicated

Absolute Contraindications

Teriparatide

·Paget's disease of bone (increased baseline osteosarcoma risk)
·Unexplained elevated alkaline phosphatase
·Prior skeletal radiation therapy
·Skeletal malignancies or bone metastases
·Hypercalcemic disorders (primary hyperparathyroidism)
·Pregnancy / lactation

Tesofensine

·Pregnancy / breastfeeding
·Severe cardiovascular disease
·Concurrent MAOI use

Relative Contraindications

Teriparatide

·Active or recent nephrolithiasis
·Severe renal impairment (CKD G4-G5)
·Hypercalciuria without adequate monitoring

Tesofensine

·Hypertension
·Anxiety disorder
·Insomnia

05Administration Protocol

Parameter

Teriparatide

Tesofensine

1. Device preparation

Teriparatide is supplied in pre-filled pen injectors (Forteo pen). Store refrigerated at 2-8 °C until first use. After first injection, pen may be kept at room temperature for up to 28 days. Do not freeze.

Oral capsule (investigational; not commercial).

2. Injection site

Subcutaneous injection into thigh or lower abdomen. Rotate sites daily to avoid lipodystrophy. Avoid areas with scars, bruises, or active skin conditions.

Swallow whole with water, morning only.

3. Timing

Once daily, at approximately the same time each day. Morning or evening administration is acceptable. Take while sitting or lying down to minimize orthostatic hypotension risk.

Morning to mitigate insomnia. Do not dose evening.

4. Injection technique

Clean injection site with alcohol swab. Pinch skin, insert needle at 90° angle, and inject full dose (20 mcg). Hold for 5 seconds before withdrawing needle. Do not rub injection site.

Room temp ≤25 °C, dry place.

5. Monitoring

Baseline and periodic monitoring of serum calcium, urinary calcium, serum PTH (if hypoparathyroidism), and bone mineral density (DXA scan). Monitor for hypercalcemia 4-6 hours post-dose if symptomatic.

Monitor BP + HR + mood. Avoid stimulants + MAOIs.

6. Calcium and vitamin D supplementation

Ensure adequate calcium (1000-1200 mg/day) and vitamin D (800-1000 IU/day) intake unless contraindicated by hypercalcemia or hypercalciuria.

—